anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The majority of patients with psychosis experience hallucinations, particularly auditory hallucinations are frequent. The hallucinations often leads to massive distress and impairments in social functioning and sometimes even order patients to commit acts of violence against themselves or others. The standard treatment for auditory hallucinations is antipsychotic medication. However, side-effects can be severe and about 25-30% of the patients do not respond to the medication. Transcranial direct current stimulation is a non-invasive brain stimulation technique, which modulates cortical excitability in a pain-free free with mild transient adverse effects, if any. Typically, cortical excitability underneath the anode is boosted while cathodal stimulation has inhibitory effects. Previous studies found that 2 daily sessions of 20 min tDCS for five subsequent days may reduce auditory hallucinations. Investigators want to further assess the efficacy of tDCS in sample that is large enough to detect medium to large effects. In addition, investigators want to investigate the neural mechanisms that underlie the tDCS treatment by examining various neuroimaging parameters before, immediately after treatment, and 3 months after treatment.
PURPOSE:An artificial saliva, containing hydroxypropyl cellulose as a viscosity increasing agent, having a very small change in the viscosity within a wide pH range, and capable of recovering the viscosity after heating and cooling to almost the viscosity before the heating. CONSTITUTION:An artificial saliva containing hydroxypropyl cellulose (HPC) in place of sodium carboxymethyl cellulose (CMC-Na) which has been used as a viscosity increasing agent. Hydroxypropyl cellulose, having 53.4-77.5% substitution degree of hydroxypropyl groups and 2.0-4.2 average number of added moles, and specified in the Japanese Pharmacopoeia is used as the HPC. Preferably, the average molecular weight thereof is 250,000-400,000, and the average polymerization degree is 700-1,000. The artificial saliva has a low viscosity in the same concentration of HPC as the CMC-Na, but exhibits the equal evaporation ability of water. The HPC has a higher solubility than the CMC-Na, and the compounding or the formulating in a large amount is facilitated.
A first set of user data is received and a user profile is constructed based on the user data and in accordance with a sensitive service involving the user. A situational context is analyzed based on the first set of data. Personalized questions are generated, responsive to the user profile and to the situational context. The personalized questions are presented to a user corresponding to the user data and responses to same are received, including detection of user micro-expressions. The responses are analyzed, according to one or more machine learning models. A neural network model selects an action to be performed in response to analyzing the responses from the user; the action is a sensitive service involving the user. An apparatus is triggered to send a simple message service (SMS) message to a point of care service professional; the message recommends performance of the sensitive service on the user.
Absorption: The estimated oral bioavailability of immediate release metoprolol is about 50% because of pre-systemic metabolism which is saturable leading to non-proportionate increase in the exposure with increased dose. 

Distribution: Metoprolol is extensively distributed with a reported volume of distribution of 3.2 to 5.6 L/kg. About 10% of metoprolol in plasma is bound to serum albumin. Metoprolol is known to cross the placenta and is found in breast milk. Metoprolol is also known to cross the blood brain barrier following oral administration and CSF concentrations close to that observed in plasma have been reported. Metoprolol is not a significant P-glycoprotein substrate. 

Metabolism: Metoprolol is primarily metabolized by CYP2D6. Metoprolol is a racemic mixture of R- and S- enantiomers, and when administered orally, it exhibits stereoselective metabolism that is dependent on oxidation phenotype. CYP2D6 is absent (poor metabolizers) in about 8% of Caucasians and about 2% of most other populations. Poor CYP2D6 metabolizers exhibit several-fold higher plasma concentrations of metoprolol than extensive metabolizers with normal CYP2D6 activity thereby decreasing metoprolol’s cardioselectivity. 

Elimination: Elimination of metoprolol is mainly by biotransformation in the liver. The mean elimination half-life of metoprolol is 3 to 4 hours; in poor CYP2D6 metabolizers the half-life may be 7 to 9 hours. Approximately 95% of the dose can be recovered in urine. In most subjects (extensive metabolizers), less than 5% of an oral dose and less than 10% of an intravenous dose are excreted as unchanged drug in the urine. In poor metabolizers, up to 30% or 40% of oral or intravenous doses, respectively, may be excreted unchanged; the rest is excreted by the kidneys as metabolites that appear to have no beta blocking activity. The renal clearance of the stereo-isomers does not exhibit stereo-selectivity in renal excretion.
A method and system for single form and single click creation of a patient visit medical record via the Internet (Online Medical Record—OMR) this is simultaneously integrated with the financial requirements of the healthcare provider. There are two components to a patient visit: 1) the medical data needed to care for the patient, and 2) the financial data required to pay for the services. The system of this invention provides for better work flow in processing both medical data, patient care, and financial coverage. The first step includes a single page creation of the OMR visit form. The OMR is hosted on a server, presented over the Internet as a single scrollable HTML page, and filled in at the user's location. The second procedure is that the foregoing page contains in juxtaposition and for use drop down lists (DDLs), List Boxes (LBs), Text Entry Boxes, Profile function buttons, and search function buttons built into the page at the point of need to facilitate data entry and work flow. The third procedure is the joining on this same page of both the medical data and the financial data related to the medical visit. The diagnosis and plan section of the medical visit includes the visit CPT coes, the ICD9 diagnosis codes, in-house procedure codes, outside procedure codes, outside lab or health care provider, medication prescribed, pharmacies selected, referred provider, notes concerning the visit and return times schedule. This same medical data is required for billing information, i.e., the visit/CPT charges, procedure changes, ICD-9 data, and related numeric value charges. The data that is embodied in the medical visit is also available for outside services to direct the care of the patient, i.e., tests, prescriptions or referral. The fourth procedure of the system is that in response to a single selection of the SAVE button, the client system sends all the medical and financial data to the server system. The server system receives the information, updates the OMR, and initiates all medical and financial processes and updates pertinent queues for further processing.
The phytocannabinoid tetrahydrocannabivarin (THCV, THV) for use in the protection of pancreatic islet cells, preferably beta cells, wherein the protection of pancreatic islet cells preferably maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient. Preferably the protection of the pancreatic islet cells supports the treatment of diabetic or pre-diabetic patients wherein the patient may have or is pre-disposed to type I diabetes, type II diabetes or gestational diabetes. THCV for use in the treatment of type I diabetes or as an oral anti-diabetic medication are outlined. THCV for use as a GLP-1 (glucagon-like peptide-1) agonist class of medication is also provided. The THCV may be present as a synthetic or an isolated phytocannabinoid, as an extract from a cannabis plant or as a botanical drug substance. Preferably the THCV is substantially free from tetrahydrocannabinol (THC) and/or cannabidiol (CBD)
Patients with ileostomy have impaired quality of life related to their ileostomy (Person et al. DCR. 2012; 55: 783 - 787; Scarpa et al. Colorectal Dis. 2010; 12: 914 - 920). Although patients with ileostomy have better overall quality of life compared with colostomy patients (Silva et al. Worl J Surg. 2003; 27: 421-424), the liquid nature of the ileostomy effluent predisposes these patients to bag overfilling and dehydration more so than colostomy patients (Paquette et al. DCR 2013; 56: 974-979). This may be specifically important in populations with long term or permanent ileostomy. Overfilling and breakage/leakage of the ileostomy bag can also affect patient's ability to function in social environments, go out in public, have intimate relationships with significant others, and interfere with sleep patterns (due to high output and nighttime overfilling of the ileostomy bag).

The Ostom-i Alert is a novel device developed by a patient with ileostomy and now FDA approved in the United States. The device is a sensor that clips onto any ostomy bag and sends a Bluetooth signal to a mobile device app. An alarm lets the patient know before the stoma bag is at risk for overfilling and leaking. The potential advantage is that the device can prevent unexpected bag overfilling, breakage, and nighttime accidents. This may therefore lead to improved quality of life. The volume and output recordings can also be stored and emailed to the patient's health care providers, with potential to reduce ostomy related dehydration through more accurate volume recording and sharing.

While the device has many applications, the purpose of this research study is to specifically evaluate patient quality of life after application of the Ostom-i Alert compared with standard ostomy care.
Introduction: Predicting postoperative incontinence beforehand is crucial for intensified and personalized rehabilitation after robot-assisted radical prostatectomy. Although nomograms exist, their retrospective limitations highlight artificial intelligence (AI)'s potential. This study seeks to develop a machine learning algorithm using robot-assisted radical prostatectomy (RARP) data to predict postoperative incontinence, advancing personalized care. Materials and Methods: In this propsective observational study, patients with localized prostate cancer undergoing RARP between April 2022 and January 2023 were assessed. Preoperative variables included age, body mass index, prostate-specific antigen (PSA) levels, digital rectal examination (DRE) results, Gleason score, International Society of Urological Pathology grade, and continence and potency questionnaires responses. Intraoperative factors, postoperative outcomes, and pathological variables were recorded. Urinary continence was evaluated using the Expanded Prostate cancer Index Composite questionnaire, and machine learning models (XGBoost, Random Forest, Logistic Regression) were explored to predict incontinence risk. The chosen model's SHAP values elucidated variables impacting predictions. Results: A dataset of 227 patients undergoing RARP was considered for the study. Post-RARP complications were predominantly low grade, and urinary continence rates were 74.2%, 80.7%, and 91.4% at 7, 13, and 90 days after catheter removal, respectively. Employing machine learning, XGBoost proved the most effective in predicting postoperative incontinence risk. Significant variables identified by the algorithm included nerve-sparing approach, age, DRE, and total PSA. The model's threshold of 0.67 categorized patients into high or low risk, offering personalized predictions about the risk of incontinence after surgery. Conclusions: Predicting postoperative incontinence is crucial for tailoring rehabilitation after RARP. Machine learning algorithm, particularly XGBoost, can effectively identify those variables more heavily, impacting the outcome of postoperative continence, allowing to build an AI-driven model addressing the current challenges in post-RARP rehabilitation.
Emerging cloud storage technology has significantly improved the efficiency and productivity of traditional electronic medical fields. However, it also presents a number of challenges, network security being a primary concern. Key policy based attribute encryption (KP-ABE) has great potential in achieving fine-grained access control, and can provide strong security for medical data in a cloud environment. However, the existing scheme still faces the problems of complex access structure, low computing power and the like. In order to solve the problems, an efficient weighted attribute encryption method (EKP-WABE) in a cloud medical environment is provided. The method uses a shorter ciphertext and a private key structure, adopts symmetric encryption and hash algorithm to replace bilinear operation, and remarkably improves encryption and decryption efficiency; the traditional threshold value gate is expanded into a weighted threshold value gate, so that the structure is simpler; theoretical analysis and experiments show that the method is more efficient than other existing methods.
The term temporomandibular disorders (TMD), according to the American American Dental Association (ADA), refers to a group of disorders characterized by pain in the temporomandibular joint (TMD) in the periauricular area or in the masticatory muscles, in addition to TMD sounds during jaw function and deviation or restriction of jaw movements. Its multifactorial etiology is related to a heterogeneous group of functional, structural, and psychological factors, making it difficult to identify the association between a single etiological factor and the signs and symptoms of TMD. As a treatment option, it hasphotobiomodulation, using different light sources, alone or in combination. These studies aim to validate the effects of photobiomodulation using clusters of 850nm LEDs (infrared) and 630nm LEDs (red); in pain and cervical and mandibular mobility in patients with TMD. It is a randomized, controlled, and blind clinical trial, which will consist of n= 36, of both genders, with ages ranging from 18 to 45 years, divided into 2 groups: Group 1 Red and infrared LED cluster, Group 2 placebo. The areas where they will receive photobiomodulation will be the TMJ area, masseter muscles, temporal muscles, scalenes, and trapezius. 6 non-consecutive sessions will be performed over 2 weeks. Diagnostic Criteria for Temporomandibular Disorders - DC/TMD will be used to determine TMD and validate participants. To validate the mandibular range of motion (ADM) a pachymeter will be used and for the cervical ADM a goniometer (fleximeter). The pain will be validated using the visual analog scale-VAS. All participants will be evaluated after the first therapeutic intervention, and again at the end, following the same validation procedures used initially.
A hair care composition comprises: (i) a water soluble ester of formula RCOXR', wherein R is an optionally substituted alkyl, alkenyl or aryl group including a hydrocarbyl group of at least 5 carbon atoms; R' includes a water solubilising group; and X is O, S or NR", wherein R" ishydrogen or an alkyl group; and (ii) an oil. Component (i) may comprise a polysorbate, such as polysorbate 80. Preferably the oil is a plant oil selected from olive oil, coconut oil, and sweet almond oil. Component (i) may be present at from 20 to 50wt%. The composition may comprise a silicone such as PEG-12 dimethicone. A method of treating hair comprises contacting the hair with the composition, and may be carried out prior to shampooing.
Patients undergo SBRT and receive APRI (abiraterone and prednisone, apalutamide, darolutamide, or enzalutamide) and ADT (leuprolide, triptorelin, histrelin, goserelin, degarelix, or relugolix). Cycles repeat every 4 months (16 weeks) for up to 6 months in the absence of unacceptable toxicity. Patients then undergo watchful waiting thereafter until disease progression.
The invention relates to a medicine capsule used for adjusting the plasma immunity. Each of the medicine dose unit contains 1 to 500mg plasma protein. The medicine takes a poultry egg as an adhesive agent. The fresh plasma is added into the poultry egg for full agitation, then dried and crushed into powder, and then the powder is added into the capsules. The medicine capsule can stimulate the immunity action, thus achieving the aim of health care and curing and preventing diseases. As the amount of the effective ingredients is small, no adverse drug reaction is occurred. Seen through the treatment to body aches, bronchial asthma, epilepsy, inflammatory aches, Meniere disease, etc., the capsule achieves good result.
BACKGROUND: The trigeminal spinal subnucleus caudalis (Sp5C), also known as the medullary dorsal horn, receives orofacial somatosensory inputs, particularly nociceptive inputs, from the trigeminal nerve. In the Sp5C, excitatory and inhibitory neurons, glutamatergic and GABAergic/glycinergic neurons, respectively, form the local circuits. The axons of the glutamatergic neurons in lamina I ascend toward the thalamic and parabrachial nuclei, and this projection is the main pathway of orofacial nociception. Additionally, the axons of the higher brain regions, including the locus coeruleus, dorsal raphe, and cerebral cortex, are sent to the Sp5C.
HIGHLIGHT: Among these descending projections, this review focuses on the functional profiles of the corticotrigeminal projections to the Sp5C, along with their anatomical aspects. The primary and secondary somatosensory and insular cortices are of particular interest.
CONCLUSION: Corticotrigeminal projections from the somatosensory cortex to the Sp5C play a suppressive role in nociceptive information processing, whereas recent studies have demonstrated a facilitative role of the insular cortex in nociceptive information processing at the Sp5C level.
If possible, discontinue PRADAXA 1 to 2 days (CrCl ≥50 mL/min) or 3 to 5 days (CrCl <50 mL/min) before invasive or surgical procedures because of the increased risk of bleeding. Consider longer times for patients undergoing major surgery, spinal puncture, or placement of a spinal or epidural catheter or port, in whom complete hemostasis may be required [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. 

If surgery cannot be delayed, there is an increased risk of bleeding [see Warnings and Precautions (5.2)]. This risk of bleeding should be weighed against the urgency of intervention [see Warnings and Precautions (5.1, 5.3)]. Use a specific reversal agent (idarucizumab) in case of emergency surgery or urgent procedures when reversal of the anticoagulant effect of dabigatran is needed. Refer to the idarucizumab prescribing information for additional information. Restart PRADAXA as soon as medically appropriate.
Patients receive maintenance daratumumab and hyaluronidase-fihj SC over 3-5 minutes on day 1 of each cycle. Cycles repeat every 28 days for up 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography at screening, 12 months post consolidation treatment and at progression. Patients undergo bone marrow aspiration and biopsy 12 months post consolidation treatment and at progression. Patients undergo blood and urine sample collection at screening, during treatment, 12 months post consolidation treatment and during follow up or at progression.
The invention discloses radix phytolaccae liquor which is prepared through conventional technologies from following components, by weight, 80 parts of radix phytolaccae, 80 parts of asparagus cochinchinensis, 20 parts of fine mix-prepared HgCl2 powder, 20 parts of roots and barks of lycium chinensis, 10 parts of euphorbia kansui, 5 parts of scrophularia ningpoensis, 15 parts of bezoar from monkeys and 1000 parts of liquor. The components, except the liquor, are placed in a container with addition of the liquor. The container is sealed and the components are soaked in the liquor for 15 days. Filtration is carried out to remove residues to obtain the radix phytolaccae liquor. The radix phytolaccae liquor has effects of nourishing and fortifying body, tonifying lung and boosting qi, moistening skin and freeing excretion, is mainly used for eliminating scars and various diseases. The radix phytolaccae liquor is taken orally with a dosage being 10-20ml by two times per day.
There was no increase in neoplasms among B6C3F1 mice given gatifloxacin in the diet for 18 months at doses averaging 81 mg/kg/day in males and 90 mg/kg/day in females. These doses are approximately 1600-fold and 1800-fold higher, respectively, than the maximum recommended ophthalmic dose of 0.05 mg/kg/day in a 50 kg human. 

There was no increase in neoplasms among Fischer 344 rats given gatifloxacin in the diet for 2 years at doses averaging 47 mg/kg/day in males and 139 mg/kg/day in females (900- and 2800-fold higher, respectively, than the maximum recommended ophthalmic dose). A statistically significant increase in the incidence of large granular lymphocyte (LGL) leukemia was seen in males treated with a high dose of approximately 2000-fold higher than the maximum recommended ophthalmic dose. Fischer 344 rats have a high spontaneous background rate of LGL leukemia and the incidence in high-dose males only slightly exceeded the historical control range established for this strain. 

In genetic toxicity tests, gatifloxacin was positive in 1 of 5 strains used in bacterial reverse mutation assays: Salmonella strain TA102. Gatifloxacin was positive in in vitro mammalian cell mutation and chromosome aberration assays. Gatifloxacin was positive in in vitro unscheduled DNA synthesis in rat hepatocytes but not human leukocytes. Gatifloxacin was negative in in vivo micronucleus tests in mice, cytogenetics test in rats, and DNA repair test in rats. The findings may be due to the inhibitory effects of high concentrations on eukaryotic type II DNA topoisomerase. 

There were no adverse effects on fertility or reproduction in rats given gatifloxacin orally at doses up to 200 mg/kg/day (approximately 4000-fold higher than the maximum recommended ophthalmic dose for ZYMAXID®).
Children have been disproportionately affected by the COVID-19 pandemic. Despite evidence of a very low risk of severe disease, children were subjected to extensive lockdown, restriction and mitigation measures, including school closures, to control the rapid spread of SARS-CoV-2 in most parts of the world. In this review we summarise the UK experience of COVID-19 in children four years into the largest and longest pandemic of this century. We address the risks of SARS-CoV-2 infection, immunity, transmission, severity and outcomes in children. We also assess the implementation, uptake, effectiveness and impact of COVID-19 vaccination, as well as the emergence, evolution and near disappearance of PIMS-TS (paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2) and current understanding of long COVID in children. This review consolidates current knowledge on childhood COVID-19 and emphasises the importance of continued research and the need for research-driven public health actions and policy decisions, especially in the context of new variants and future vaccines.